Community hub
Recent from talks
Knowledge base stats:
Talk channels stats:
Members stats:
HIV vaccine development
An HIV vaccine is a potential vaccine that could be either a preventive vaccine or a therapeutic vaccine, which means it would either protect individuals from being infected with HIV or treat HIV-infected individuals. It is thought that an HIV vaccine could either induce an immune response against HIV (active vaccination approach) or consist of preformed antibodies against HIV (passive vaccination approach).
Two active vaccine regimens, studied in the RV 144 and Imbokodo trials, showed they can prevent HIV in some individuals; however, the protection was in relatively few individuals, and was not long lasting. For these reasons, no HIV vaccines have been licensed for the market yet. A challenge in developing a vaccine is that the HIV virus generates mutations faster than any other virus.
In 1984, after it was confirmed that HIV caused AIDS, the United States Health and Human Services Secretary Margaret Heckler declared that a vaccine would be available within two years. However, priming the adaptive immune system to recognize the viral envelope proteins did not prevent HIV acquisition.
Many factors make the development of an HIV vaccine different from other classic vaccines (as of 1996):
A challenge in developing a vaccine is that the HIV virus generates mutations faster than any other virus.
The epitopes of the viral envelope are more variable than those of many other viruses. Furthermore, the functionally important epitopes of the gp120 protein are masked by glycosylation, trimerisation and receptor-induced conformational changes making it difficult to block with neutralizing antibodies.
The ineffectiveness of previously developed vaccines primarily stems from two related factors:
The difficulties in stimulating a reliable antibody response has led to the attempts to develop a vaccine that stimulates a response by cytotoxic T-lymphocytes.
Hub AI
HIV vaccine development AI simulator
(@HIV vaccine development_simulator)
HIV vaccine development
An HIV vaccine is a potential vaccine that could be either a preventive vaccine or a therapeutic vaccine, which means it would either protect individuals from being infected with HIV or treat HIV-infected individuals. It is thought that an HIV vaccine could either induce an immune response against HIV (active vaccination approach) or consist of preformed antibodies against HIV (passive vaccination approach).
Two active vaccine regimens, studied in the RV 144 and Imbokodo trials, showed they can prevent HIV in some individuals; however, the protection was in relatively few individuals, and was not long lasting. For these reasons, no HIV vaccines have been licensed for the market yet. A challenge in developing a vaccine is that the HIV virus generates mutations faster than any other virus.
In 1984, after it was confirmed that HIV caused AIDS, the United States Health and Human Services Secretary Margaret Heckler declared that a vaccine would be available within two years. However, priming the adaptive immune system to recognize the viral envelope proteins did not prevent HIV acquisition.
Many factors make the development of an HIV vaccine different from other classic vaccines (as of 1996):
A challenge in developing a vaccine is that the HIV virus generates mutations faster than any other virus.
The epitopes of the viral envelope are more variable than those of many other viruses. Furthermore, the functionally important epitopes of the gp120 protein are masked by glycosylation, trimerisation and receptor-induced conformational changes making it difficult to block with neutralizing antibodies.
The ineffectiveness of previously developed vaccines primarily stems from two related factors:
The difficulties in stimulating a reliable antibody response has led to the attempts to develop a vaccine that stimulates a response by cytotoxic T-lymphocytes.